Skip to content

Study · Non-randomized trial · 2011

2 results

[Comparative aspects of using neuroprotectors in the management of patients with ischemic stroke].

Ershov VI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2011Cited by 4 (Europe PMC)

PMID22224244 (opens in a new tab)PepBankPUB-22224244
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke patients, cerebrolysin improved neurological symptom regression by the 21st day compared with basic treatment alone.

    In plain wordsIn stroke patients, cerebrolysin improved neurological symptoms more than basic treatment alone.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeurological symptom regression
    Study

    n: not reported in source

    Comparator
    Basic treatment without neuroprotectors
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml daily · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Ceraxon in daily dosage 2 g and cerebrolysin in daily dosage 10 ml during 10 days after the development of ischemic stroke led to the significantly better regression of neurological symptoms to the 21st day of disease compared to the control group.
    2 context sentences
    Summary · context
    Comparative efficacy of neuroprotective preparations: actovegin, cerebrolysin and ceraxon was studied in 73 patients in the most acute phase of ischemic stroke.
    Summary · context
    A control group included 33 patients in the most acute phase of ischemic stroke who received only basic treatment without neuroprotectors.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acute ischemic stroke patients, Barthel index scores did not differ among the study groups, including cerebrolysin.

    In plain wordsIn stroke patients, daily activity scores did not differ among groups, including cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeBarthel index
    Study

    n: not reported in source

    Comparator
    Other study groups
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    10 ml daily · 10 daysAs given in this study (human).

    Source sentences

    Summary
    Barthel index scores did not differ in the groups studied.
    3 context sentences
    Summary · context
    Ceraxon in daily dosage 2 g and cerebrolysin in daily dosage 10 ml during 10 days after the development of ischemic stroke led to the significantly better regression of neurological symptoms to the 21st day of disease compared to the control group.
    Summary · context
    Comparative efficacy of neuroprotective preparations: actovegin, cerebrolysin and ceraxon was studied in 73 patients in the most acute phase of ischemic stroke.
    Summary · context
    A control group included 33 patients in the most acute phase of ischemic stroke who received only basic treatment without neuroprotectors.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.